CSL Behring Announces First Two Patients Treated With HEMGENIX® (etranacogene Dezaparvovec) Gene Therapy For Hemophilia B In Europe
MARBURG, Germany, July 4 (Bernama-GLOBE NEWSWIRE) — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the first gene therapy administered as a treatment in a real-world setting for hemophilia…

